Cholestyramine and Duphalac drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cholestyramine (cholestyramine) and Duphalac (lactulose). Common drug interactions include colitis ischaemic among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Cholestyramine and Duphalac. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Cholestyramine?

Cholestyramine has active ingredients of cholestyramine. It is often used in diarrhea. eHealthMe is studying from 9,893 Cholestyramine users. Check the latest studies of Cholestyramine.

What is Duphalac?

Duphalac has active ingredients of lactulose. It is often used in constipation. eHealthMe is studying from 5,152 Duphalac users. Check the latest studies of Duphalac.

On Jul, 17, 2026

11 people who take Cholestyramine and Duphalac together, and have interactions are studied.

Cholestyramine and Duphalac drug interactions.

What are the common drug interactions of Cholestyramine and Duphalac, by gender? *:

female:

Colitis ischaemic (due to infection of intestine impaired blood supply to colon)

male:

Death
Diffuse alveolar damage (common manifestation of drug-induced lung injury)
Pulmonary interstitial emphysema syndrome (collection of gases outside of the normal air passages and inside the connective tissue of the peribronchovascular sheaths, interlobular septa, and visceral pleura of lungs)
Rash maculo-papular (red area on the skin that is covered with small confluent bumps)
Rectal haemorrhage (bleeding from anus)
Restlessness (not able to rest)
Sepsis (a severe blood infection that can lead to organ failure and death)
Thrombocytopenia (decrease of platelets in blood)
Dyspnoea (difficult or laboured respiration)
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)

What are the common drug interactions of Cholestyramine and Duphalac, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Death
Diffuse alveolar damage (common manifestation of drug-induced lung injury)
Pulmonary interstitial emphysema syndrome (collection of gases outside of the normal air passages and inside the connective tissue of the peribronchovascular sheaths, interlobular septa, and visceral pleura of lungs)
Rash maculo-papular (red area on the skin that is covered with small confluent bumps)
Rectal haemorrhage (bleeding from anus)
Restlessness (not able to rest)
Sepsis (a severe blood infection that can lead to organ failure and death)
Thrombocytopenia (decrease of platelets in blood)
Colitis ischaemic (due to infection of intestine impaired blood supply to colon)
Dyspnoea (difficult or laboured respiration)

What are the existing conditions these people have? *

Skin Infection: 10 people, 90.91%
Multiple Myeloma (cancer of the plasma cells): 1 person, 9.09%
Insomnia (sleeplessness): 1 person, 9.09%
Cough: 1 person, 9.09%
Abdominal Pain Upper: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Cholestyramine and Duphalac?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously